Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047584 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21719818 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11015815 | 1.00 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19186683 | 0.98 | CYP19A1 (0.36) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21191816 | 0.97 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25627105 | 0.90 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17803621 | 0.89 | CYP1A2 (0.31) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22059382 | 0.86 | CYP19A1 (0.37) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27922362 | 0.84 | CYP19A1 (0.38) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11306595 | 0.82 | CYP19A1 (0.39) | CYP19A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | KLKB1, F2, SERPINC1 | CYP19A1 227/4885CYP1A2 385/4885CYP3A4 436/4885 |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | CYP19A1 2473/4885CYP1A2 2350/4885CYP3A4 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.